Welcome to our dedicated page for Teladoc Health SEC filings (Ticker: TDOC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Teladoc Health, Inc. executive Kelly Bliss, President, U.S. Group Health, reported an open-market sale of common stock. On June 29, 2026, she sold 2,500 shares of Teladoc Health common stock at $8.50 per share.
The filing states that this transaction was executed under a Rule 10b5-1 trading plan adopted on August 14, 2025, indicating it was pre-arranged rather than timed discretionarily. After this sale, Bliss directly holds 89,878 shares of Teladoc Health common stock.
Telehealth Group affiliate files a Form 144 proposing resale of securities. The notice lists 2,500 shares tied to Restricted Stock Vesting with a 06/01/2025 vesting date and records 7,679 shares sold in the prior three months for $58,567.73. The broker listed is Fidelity Brokerage Services LLC.
Teladoc Health (Common Stock) ownership disclosure: a group led by Voss entities and Travis W. Cocke reports beneficial ownership stakes in the issuer. The filing lists specific holdings by entity, including 9,025,722 shares held by Voss Capital/Cocke-affiliated accounts and related entities and references 180,513,087 shares outstanding as of April 23, 2026.
The schedule states that Voss Value Master Fund beneficially owns 1,803,606 shares (including 700,000 shares underlying currently exercisable call options), Voss Value-Oriented Special Situations Fund owns 200,000 shares, and Voss GP may be deemed to beneficially own both fund holdings. The filing attributes approximately 5.00% beneficial ownership to Voss Capital and to Travis W. Cocke on an aggregate basis, and smaller percentages to the other named reporting persons.
Teladoc Health, Inc. CEO Charles DiVita III reported a mix of equity compensation activity and related share sales. On June 10, 2026, he exercised restricted stock units and performance stock units that convert one-for-one into common shares, receiving 39,160 and 3,642 shares of common stock, respectively.
On June 11, 2026, he sold 18,074 shares of common stock at $6.942 per share. A footnote states these shares were sold to cover the tax withholding obligation from the vesting of his performance and restricted stock unit awards, rather than as a discretionary open-market sale for liquidity.
After these transactions, DiVita directly holds 414,622 shares of Teladoc common stock. Footnotes also note he earned 23,591 performance stock units on June 10, 2026, scheduled to vest partially on March 10, 2026 with the remainder in five quarterly installments, and that a prior grant of 469,924 restricted stock units from June 10, 2024 continues to vest over time.
Fidelity Brokerage Services LLC submitted a Form 144 notice relating to 18,074 shares of Common Stock proposed for sale following a Restricted Stock Vesting event on 06/10/2026. The filing records the shares as compensation issued by the Issuer.
Separately, the excerpt shows prior sales by Charles Divita of 27,731 shares on 03/11/2026 and 19,132 shares on 06/02/2026, with dollar amounts noted in the table.
Teladoc Health, Inc. executive Fernando M. Rodrigues, President of BetterHelp, reported an open-market sale of 9,572 shares of common stock at $7.40 per share. Following this transaction, his directly held common stock position in this account was reduced to 0 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 3, 2025, indicating the trades were scheduled in advance.
Teladoc Health, Inc. executive Fernando M. Rodrigues, President of BetterHelp, reported a combination of stock vesting and related share sales. On June 1, 2026, restricted stock units converted into 15,249 shares of Teladoc common stock, reflecting compensation awards that vest over time.
On June 2, 2026, Rodrigues sold 5,677 shares of common stock at an average price of $7.627 per share to cover the tax withholding obligation tied to this RSU vesting. After these transactions, he directly held 9,572 shares of Teladoc common stock, while continuing to hold additional restricted stock units that convert to common stock on a one-for-one basis as they vest.
Teladoc Health, Inc. insider Adam C. Vandervoort, the company’s Chief Legal Officer and Secretary, reported equity compensation vesting and related share sales. On June 1, 2026, restricted stock units and performance stock units converted on a one-for-one basis into a total of 14,928 shares of common stock. On June 2, 2026, he sold 7,906 shares of common stock at $7.627 per share to satisfy the tax withholding obligation tied to these vesting awards. Following these transactions, Vandervoort directly owned 110,261 shares of Teladoc common stock.
Teladoc Health, Inc. reported that Carlos Nueno, its President, International, exercised restricted stock units and sold shares primarily to cover taxes. On June 1, 2026, he converted a total of 13,272 restricted stock units into the same number of Teladoc common shares at a conversion price of $0.00 per share, with the units converting on a one-for-one basis into common stock.
On June 2, 2026, Nueno sold 6,196 shares of common stock at an average price of $7.627 per share. A footnote explains these shares were sold to cover the tax withholding obligation related to the vesting of his restricted stock unit awards, indicating a tax-driven disposition rather than a discretionary open-market sale. After these transactions, he directly held 57,671 shares of Teladoc common stock and 13,670 restricted stock units.
The filing also notes earlier equity grants, including 54,675 restricted stock units granted on March 19, 2024 and 104,602 restricted stock units granted on March 1, 2025, both subject to multi-year vesting schedules. These awards illustrate that a significant portion of Nueno’s compensation remains tied to Teladoc’s future share performance through ongoing RSU vesting.
Teladoc Health, Inc. chief executive officer Charles Divita III reported compensation-related stock activity. On June 1, 2026, previously granted restricted stock units and performance stock units converted into a total of 44,242 shares of common stock on a one-for-one basis.
On June 2, 2026, he sold 19,132 shares of common stock at $7.627 per share, with the footnotes stating the shares were sold to cover tax withholding obligations tied to the vesting of these awards. After the transactions, he directly owned 389,894 common shares.